Alpha1-Proteinase Inhibitor
- Atc Codes:B02AB
Table of contents
- Brand Names
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Prolastin; Denmark: Prolastina; France: Alfalastin; Germany: Prolastin; Ireland: Prolastin; Italy: Prolastina; Netherlands: Prolastin; Poland: Prolastin; Portugal: Prolastin; Spain: Prolastina; Sweden: Prolastina.
North America
Canada: Prolastin; USA: Aralast, Prolastin, Zemaira.
Latin America
Argentina: Prolastín, Trypsan.
Drug combinations
Chemistry
Pharmacologic Category
Antihemorrhagic Agents; Proteinase Inhibitors. (ATC-Code: B02AB).
Mechanism of action
Serum protease inhibitor. Inactivates proteolytic enzymes (secreted during inflammation).
Therapeutic use
Replacement therapy in congenital α~1~-antitrypsin deficiency with clinical emphysema.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to any component of the formulation or alpha~1~-proteinase inhibitor products. Selective IgA deficiency with known anti-IgA antibody.
Warnings and precautions
Hypersensitivity and anaphylactic reactions may occur in patients with anti-IgA antibody. Hepatitis B (consider immunization). Product of human plasma (may contain infectious agents). Use with caution in patients at risk for fluid overload.